Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Food and Famotidine on BMS-986165 Bioavailability in Healthy Volunteers
NCT04209699Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucravacitinib in plaque psoriasis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration (Cmax) for BMS-986165 (Fed vs Fasted), Maximum observed plasma concentration (Cmax) for BMS-986165 (Famotidine vs Alone) and 4 more. Started Dec 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04209699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209699.